Table 3.

Cytogenetic and Molecular Response to DAS at Different Time Points

	3rd Month	6th Month	12th Month
Too early	/	1	7
Evaluable	65	64	58
Not done	6 (9.3%)	6 (9.4%)	/
Discontinuation	2 (3.1%)	4 (6.2%)	7 (12.1%)
Less than CCyR	10 (15.3%)	5 (7.8%)	3 (5.1%)
CCyR*	47 (72.3%)	49 (76.6%)	48 (82.8%)
MMR	19 (29.2%)	36 (56.2%)	37 (63.8%)
MR 3.0	13	16	20
MR 4.0	4	13	9
MR 4.5	2	7	8

^*Patients at any time point with molecular analysis only and BCR-ABL1/ABL1 ratio <1.0 were also considered in CCyR.